Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03555422
Title Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO)
Acronym ENGOT-EN5
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ISR | GRC | ESP | DEU | CZE | CAN | BEL


No variant requirements are available.